Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Completed Journey
Companies On The Road
Follow The Artist
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Completed Journey
Companies We've Met
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
Novartis (2)
74 Articles Available
2
4
Can't find what you're looking for? Try our
advanced search
.
Leadership
Novartis Announces New Leader of Pharmaceuticals Business Unit
PR-M06-19-NI-024
Drug Development
Novartis Cosentyx® First to Show Efficacy in All Key Manifestations of Psoriatic Arthritis
PR-M06-19-NI-020
M&A
Novartis to Acquire Xiidra®, Expanding Front-of-Eye Portfolio
PR-M05-19-NI-034
FDA Acceptance
Novartis Announces FDA Filing Acceptance and Priority Review of Brolucizumab (RTH258) for Patients with Wet AMD
PR-M04-19-NI-053
Legal
Amgen Looking to Exit Migraine Collaboration with Novartis
PAO-M04-19-NI-015
Acquistion
Novartis Acquires IFM Tre
PAO-M04-19-NI-004
Business
Alcon Going on Its Own
PAO-M03-19-NI-038
Drug Development
Novartis Licenses First-in-Class Heart Disease Drug
PAO-M03-19-NI-008
FDA
FDA Gives Novartis Gene Replacement Therapy Application Priority Review
PAO-M12-18-NI-003
FDA Approval
Novartis’ Promacta Gets Expanded Use Approval from the FDA
PAO-M11-18-NI-020
Drug Development
Novartis Grabs Attention for its Development Pipeline
PAO-M11-18-NI-011
Macular Degeneration
More Positive Results for Novartis Eye Drug Brolucizumab
PAO-M11-18-NI-002
Patent
Humira Patent Disputes between Novartis and Abbvie Settled
PAO-M10-18-NI-021
Cell and Gene Therapy
Novartis announces positive CHMP opinion for one-time gene therapy Luxturna(R) to treat children and adults with rare inherited retinal disease
PR-M09-18-NI-095
Annoucement
Novartis Unloads Sandoz US Components
PAO-M09-18-NI-011
Legal
Novartis Goes to Court Over Gilenya Generics
PAO-M07-18-NI-020
Drug Development
Novartis Will Spend Up to More Than $1 Billion on an Eczema Candidate
PAO-M07-18-NI-017
Drug Development
Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US
PR-M07-18-NI-068
Drug Development
Appeals Board Rules in Favor of Novartis and its Multiple Sclerosis Drug Gilenya
PAO-M07-18-NI-014
Announcement
Alcon Set Out On its Own
PAO-M07-18-NI-002
Announcement
Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates share buyback of up to USD 5 bn
PR-M07-18-NI-006
Clinical Data
Novartis and Amgen Highlight Findings from a Large Global Patient Survey on Migranes
PR-M06-18-NI-101
Clinical Data
Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL
PR-M06-18-NI-062
FDA Approval
Novartis and Amgen announce FDA approval of Aimovig™ (erenumab-aooe), a novel treatment developed specifically for migraine prevention
PR-M05-18-NI-081
«
2
4
»